FR3079141B1 - Utilisations de derives de curcumine - Google Patents

Utilisations de derives de curcumine Download PDF

Info

Publication number
FR3079141B1
FR3079141B1 FR1902500A FR1902500A FR3079141B1 FR 3079141 B1 FR3079141 B1 FR 3079141B1 FR 1902500 A FR1902500 A FR 1902500A FR 1902500 A FR1902500 A FR 1902500A FR 3079141 B1 FR3079141 B1 FR 3079141B1
Authority
FR
France
Prior art keywords
curcumin derivatives
subject
curcumin
tml
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1902500A
Other languages
English (en)
Other versions
FR3079141A1 (fr
Inventor
Ih-Jen Su
Kuen-Jer Tsai
Hong-Yi Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merry Life Biomedical Company Ltd
Merry Life Biomedical Co Ltd
Original Assignee
Merry Life Biomedical Company Ltd
Merry Life Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merry Life Biomedical Company Ltd, Merry Life Biomedical Co Ltd filed Critical Merry Life Biomedical Company Ltd
Publication of FR3079141A1 publication Critical patent/FR3079141A1/fr
Application granted granted Critical
Publication of FR3079141B1 publication Critical patent/FR3079141B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé de prévention et/ou de traitement de la maladie d’Alzheimer chez un sujet nécessitant un tel traitement, comprenant l’administration audit sujet d’une quantité efficace d’un dérivé de curcumine, TML-6, et éventuellement d’un excipient ou d’un vecteur pharmaceutiquement acceptables.
FR1902500A 2018-03-23 2019-03-12 Utilisations de derives de curcumine Active FR3079141B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647501P 2018-03-23 2018-03-23
US62/647,501 2018-03-23

Publications (2)

Publication Number Publication Date
FR3079141A1 FR3079141A1 (fr) 2019-09-27
FR3079141B1 true FR3079141B1 (fr) 2022-05-20

Family

ID=66380346

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1902500A Active FR3079141B1 (fr) 2018-03-23 2019-03-12 Utilisations de derives de curcumine

Country Status (8)

Country Link
US (1) US11135185B2 (fr)
JP (1) JP6814240B2 (fr)
CN (1) CN110292571B (fr)
AU (1) AU2019201665B2 (fr)
CA (1) CA3036444C (fr)
FR (1) FR3079141B1 (fr)
GB (1) GB2572259B (fr)
TW (1) TWI703975B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6814240B2 (ja) 2018-03-23 2021-01-13 メリー ライフ ビオメディカル カンパニー，リミテッドＭｅｒｒｙ Ｌｉｆｅ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｍｐａｎｙ，Ｌｔｄ． クルクミン誘導体の使用
US11793775B2 (en) * 2021-04-20 2023-10-24 Merry Life Biomedical Company, Ltd. Combined therapy for treating Alzheimer's disease
US20240156988A1 (en) * 2022-11-11 2024-05-16 Eli Lilly And Company Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123637A4 (fr) 2006-11-30 2011-12-21 Tokyo Inst Tech Nouveau dérivé curcumine
US9000222B2 (en) * 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
WO2008085984A1 (fr) 2007-01-08 2008-07-17 Androscience Corporation Composés comprenant un groupe caractéristique de propénal (substitué par du phényle), leurs dérivés, leur activité biologique et leurs utilisations
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
WO2010004579A2 (fr) 2008-07-07 2010-01-14 Laila Pharmaceuticals Pvt. Ltd. Composés curcuminoïdes actifs oralement
CN102225919B (zh) 2011-04-29 2013-11-06 中山大学 一种姜黄素类似物及其制备方法和在制备抗阿尔茨海默病药物中的应用
SG11201408387YA (en) 2012-06-18 2015-01-29 Androscience Corp Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
JP6273088B2 (ja) 2012-11-28 2018-01-31 国立大学法人滋賀医科大学 認知症の治療及び予防用の医薬組成物
CN104974038B (zh) 2014-04-13 2019-04-30 江苏康缘药业股份有限公司 一种含羧基单羰基姜黄素衍生物及其制备方法和应用
JP6814240B2 (ja) 2018-03-23 2021-01-13 メリー ライフ ビオメディカル カンパニー，リミテッドＭｅｒｒｙ Ｌｉｆｅ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｍｐａｎｙ，Ｌｔｄ． クルクミン誘導体の使用
JP2020125285A (ja) 2019-01-04 2020-08-20 アリアンツ ファーマサイエンス リミテッド 神経変性性障害の治療方法

Also Published As

Publication number Publication date
CN110292571A (zh) 2019-10-01
CN110292571B (zh) 2022-03-08
US11135185B2 (en) 2021-10-05
GB201903361D0 (en) 2019-04-24
AU2019201665A1 (en) 2019-10-10
GB2572259A (en) 2019-09-25
CA3036444C (fr) 2021-03-23
GB2572259B (en) 2022-03-30
US20190290604A1 (en) 2019-09-26
JP2019218334A (ja) 2019-12-26
AU2019201665B2 (en) 2020-03-19
JP6814240B2 (ja) 2021-01-13
CA3036444A1 (fr) 2019-09-23
TW201940163A (zh) 2019-10-16
TWI703975B (zh) 2020-09-11
FR3079141A1 (fr) 2019-09-27

Similar Documents

Publication Publication Date Title
FR3079141B1 (fr) Utilisations de derives de curcumine
MA54227B1 (fr) Méthodes de traitement de la fibrose kystique
MA45811A (fr) Méthodes et compositions de traitement de maladie.
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
EA202092154A1 (ru) Комбинированная терапия
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020007941A (es) Metodo para prevenir o tratar enfermedad de alzheimer.
WO2020128816A3 (fr) Compositions pharmaceutiques et méthodes comprenant une combinaison d'un stabilisateur de transthyrétine benzoxazole et d'un agent thérapeutique supplémentaire
PH12019502096A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
RU2019110264A (ru) Циклическое соединение
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
PH12020551470A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
BR112022003126A2 (pt) Conjugado terapêutico
EA202193211A1 (ru) Лечение синуклеопатий

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200508

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6